X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (70) 70
female (44) 44
hematology (43) 43
male (41) 41
oncology (35) 35
middle aged (34) 34
aged (33) 33
adult (28) 28
prognosis (26) 26
aged, 80 and over (23) 23
cancer (20) 20
hemic and lymphatic diseases (18) 18
mutation (17) 17
hematology, oncology and palliative medicine (14) 14
myelofibrosis (14) 14
risk factors (14) 14
chemotherapy (13) 13
janus kinase 2 - genetics (13) 13
leukemia (13) 13
treatment outcome (13) 13
abridged index medicus (12) 12
acute myeloid leukemia (12) 12
retrospective studies (12) 12
adolescent (11) 11
leukemia, myeloid, acute - mortality (11) 11
polycythemia-vera (11) 11
primary myelofibrosis - genetics (11) 11
survival rate (11) 11
acute myelogenous leukemia (10) 10
antineoplastic agents - therapeutic use (10) 10
expression (10) 10
leukemia, myeloid, acute - drug therapy (10) 10
research (10) 10
analysis (9) 9
essential thrombocythemia (9) 9
leukemia, myeloid, acute - genetics (9) 9
myeloproliferative disorders (9) 9
remission induction (9) 9
therapy (9) 9
young adult (9) 9
animals (8) 8
follow-up studies (8) 8
polycythemia vera - genetics (8) 8
proto-oncogene proteins - genetics (8) 8
acute myeloid-leukemia (7) 7
adult patients (7) 7
health aspects (7) 7
jak2 (7) 7
mortality (7) 7
myeloproliferative disorders - genetics (7) 7
protein-tyrosine kinases - genetics (7) 7
quality of life (7) 7
survival analysis (7) 7
transplantation (7) 7
tyrosine kinase jak2 (7) 7
acute lymphoblastic-leukemia (6) 6
adults (6) 6
antineoplastic agents - adverse effects (6) 6
care and treatment (6) 6
clinical trials (6) 6
cytarabine (6) 6
elderly-patients (6) 6
gene (6) 6
genetic aspects (6) 6
janus kinase 2 (6) 6
leukemia, myeloid, acute - therapy (6) 6
mice (6) 6
myeloid metaplasia (6) 6
protein kinase inhibitors - therapeutic use (6) 6
stem cells (6) 6
stem-cell transplantation (6) 6
thrombocythemia, essential - genetics (6) 6
activating mutation (5) 5
amino acid substitution (5) 5
aml (5) 5
cell biology (5) 5
cells (5) 5
disease progression (5) 5
disease-free survival (5) 5
dna mutational analysis (5) 5
efficacy (5) 5
fms-like tyrosine kinase 3 - genetics (5) 5
gene expression profiling (5) 5
imatinib mesylate (5) 5
international working group (5) 5
jak2 mutation (5) 5
mutations (5) 5
myelodysplastic syndromes (5) 5
myelodysplastic syndromes - mortality (5) 5
myeloid neoplasia (5) 5
myeloproliferative neoplasms (5) 5
polycythemia vera (5) 5
primary myelofibrosis - pathology (5) 5
signal transduction (5) 5
survival (5) 5
transplantation, homologous (5) 5
age factors (4) 4
aged patients (4) 4
antineoplastic agents - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
PLoS medicine, ISSN 1549-1676, 2006, Volume 3, Issue 7, pp. e270 - 1151
The JAK2V617F allele has recently been identified in patients with polycythemia vera (PV), essential thrombocytosis (ET), and myelofibrosis with myeloid... 
Recombinant Fusion Proteins - adverse effects | Humans | Myeloproliferative Disorders - pathology | Mutation, Missense | Primary Myelofibrosis - pathology | Receptors, Cytokine - physiology | Janus Kinases - physiology | Bone Marrow Transplantation | Hematopoiesis - physiology | Myeloid Cells - drug effects | Transcription, Genetic | Colony-Forming Units Assay | Phosphorylation - drug effects | mRNA Cleavage and Polyadenylation Factors - genetics | Hematologic Neoplasms - physiopathology | Disease Models, Animal | Cells, Cultured - drug effects | Bone Marrow Cells - pathology | Hematopoiesis - genetics | Signal Transduction - genetics | Thrombocytosis - etiology | Sequence Analysis, DNA | Cell Division - drug effects | mRNA Cleavage and Polyadenylation Factors - physiology | Receptor, Platelet-Derived Growth Factor alpha - physiology | Hematologic Neoplasms - drug therapy | Mice | Mice, Inbred BALB C | Myeloid Cells - pathology | Protein Processing, Post-Translational - genetics | Myeloproliferative Disorders - genetics | Oncogene Proteins, Fusion - physiology | STAT Transcription Factors - physiology | Protein Processing, Post-Translational - drug effects | Cells, Cultured - pathology | Bone Marrow Cells - drug effects | Spleen - pathology | Thrombocytosis - pathology | Gene Expression Regulation | Janus Kinases - antagonists & inhibitors | Point Mutation | Megakaryocytes - pathology | Primary Myelofibrosis - genetics | Animals | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Receptor, Platelet-Derived Growth Factor alpha - genetics | Myeloproliferative Disorders - etiology | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Genetic Vectors | Megakaryocytes - drug effects | Cytokines - pharmacology | Amino Acid Substitution | Thrombocytosis - genetics | Genetic aspects | Myelofibrosis | Research | Hematology | Gene Therapy | Genomics | Genetics | Oncology | Cancer Biology | Hematology (including Blood Transfusion)
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 0027-8424, 1/2010, Volume 107, Issue 1, pp. 252 - 257
Journal Article
Blood, ISSN 1528-0020, 2015, Volume 125, Issue 9, pp. 1367 - 1376
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2013, Volume 31, Issue 7, pp. 923 - 929
Journal Article
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 10/2005, Volume 131, Issue 2, pp. 208 - 213
Summary Clinical correlates and long-term prognostic relevance of the JAK2V617F mutation was studied in 150 patients with essential thrombocythaemia (ET) from... 
JAK2 mutation | myeloproliferative disorders | prognosis | essential thrombocythaemia | Prognosis | Essential thrombocythaemia | Myeloproliferative disorders
Journal Article
British journal of haematology, ISSN 0007-1048, 2016, Volume 175, Issue 3, pp. 496 - 504
Journal Article